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Resumo 
 
A terapia génica é uma abordagem terapêutica que tem mostrado grande 
potencial para o tratamento de doenças genéticas hereditárias ou adquiridas. 
Geralmente envolve a substituição ou inibição do gene mutado ou ainda a inserção 
de um novo gene. O sucesso de uma estratégia de terapia génica depende da 
eficiência da transferência genética e da expressão estável do gene transferido. 
Atualmente existem duas abordagens que são utilizadas no desenvolvimento de 
terapias génicas: a viral e a não viral. A abordagem viral, embora seja bastante 
eficiente, levanta preocupações com a segurança a nível imunológico e mutagénico.  
Por outro lado a abordagem não-viral caracteriza-se pela sua fácil utilização, 
capacidade de empacotamento de genes ilimitada e ausência de resposta 
imunitária. Apesar destas vantagens a aplicabilidade da abordagem não-viral 
encontra-se limitada pela sua baixa eficiência de transfeção quando comparada com 
a abordagem viral; deste modo, a optimização dos vetores não-virais visa sobretudo 
a melhoria da sua eficiência de transfeção. 
O nosso objectivo era desenvolver vetores não-virais para terapia génica 
ocular, em particular da retina. Considerando o órgão alvo, o olho apresenta 
características únicas para terapia génica como por exemplo o seu reduzido 
tamanho, relativo isolamento em relação à circulação sistémica e facilidade de 
acesso a diferentes tipos de tecidos por vias de administração diferentes.  
Grande parte das estratégias de terapia génica não-viral focam-se na 
utilização de lípidos ou polímeros catiónicos, mas até à data poucos estudos foram 
feitos sobre a sua utilização no olho e em particular na retina. Os polímeros, 
quitosano e ácido hialurónico ou os polímeros modificados (quitosano tiolado e 
ácido hialurónico aminado) foram escolhidos considerando a sua biocompatibilidade 
e biodegradabilidade para a preparação de diversas formulações de vectores. Estes 
polímeros já foram utilizados com bastante sucesso em aplicações como a entrega 
de fármacos, o que, aliado às propriedades referidas anteriormente, os torna 
bastante atrativos para aplicações de terapia génica, embora seja necessária a sua 
otimização. Esta otimização engloba a modificação química dos polímeros supra-
referidos, tal como a modificação com cistamina que permite introduzir uma ponte 
dissulfeto, que pode ser clivada no meio intracelular pela glutationa, permitindo 
assim uma libertação do ADN mais facilitada. No caso do ácido hialurónico permite 
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ainda adicionar grupos amina, que poderiam interagir electrostaticamente com o 
ADN. 
Experimentalmente podemos dividir este trabalho em 3 secções: i) a 
preparação de diversas formulações de vetores com quitosano e ácido hialurónico, 
que foram caracterizadas em relação às suas propriedades físicas, nomeadamente 
tamanho, polidispersão, carga superficial, eficiência da complexação de ADN, 
capacidade de proteção contra nucleases e estabilidade dos vectores em diferentes 
condições; ii) a caraterização dos vectores in vitro em relação à sua citotoxicidade e 
eficiência de transfeção em células epiteliais pigmentadas de retina e células 
HEK293; iii) a administração in vivo dos vectores com melhores resultados in vitro  e 
a sua caracterização em relação à sua expressão génica na retina de ratinhos 
através de injeção subretiniana. 
Os nossos resultados mostram que os vetores têm tamanho e carga 
superficial adequados à entrega de genes, embora variem consoante a formulação. 
Apresentam também estabilidade a longo prazo tanto em condições de 
armazenamento como em condições fisiológicas de temperatura e pH. Os vetores 
mantêm-se estáveis após vários ciclos de congelação e descongelação e são 
capazes de proteger eficazmente o ADN da degradação por nucleases. Observou-
se também um efeito do peso molecular do quitosano nas propriedades dos vetores: 
a utilização de um polímero com maior peso molecular resultou em vetores de 
maiores dimensões com tendência para uma carga superficial superior, mas com 
uma estabilidade mais reduzida comparativamente aos vetores preparados com o 
polímero de menor peso molecular. Este efeito do peso molecular do polímero 
estendeu-se à eficiência de transfeção e vectores preparados com o polímero de 
menor peso molecular obtiveram melhores resultados. 
 Os ensaios de transfeção mostram também que a eficiência de transfeção e a 
expressão do transgene é afectada pelo tipo de células e modo de entrega da 
integrase com os poliplexos. A eficiência de transfeção foi superior em células 
HEK293 do que em células pigmentadas da retina. A elevada estabilidade dos 
poliplexos tem sido associada com uma baixa eficiência de transfeção e a utilização 
de polímeros aniónicos tem sido usada como uma das opções para solucionar essa 
questão. A incorporação de ácido hialurónico nas formulações afectou a 
estabilidade das formulações, como era esperado, mas não afectou a complexação 
nem a proteção do ADN no poliplexo. A combinação de quitosano e ácido 
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hialurónico nos poliplexos mostrou uma melhoria significativa na eficiência de 
transfeção comparada com vectores baseados apenas em quitosano.  
 Os ensaios de transfeção usando vectores preparados com os polímeros 
modificados (quitosano tiolado e ácido hialurónico aminado) não revelaram 
melhorias significativas em relação aos polímeros não modificados. Pensa-se que 
isto poderá estar associado a interferências do contra-ião de grandes dimensões – 
tosilato no caso do quitosano tiolado - e a uma baixa percentagem de modificação 
no caso do ácido hialurónico aminado. Seria necessário repetir as reações de 
modificação de modo a substituir o contra-ião por cloreto e conseguir uma 
percentagem de modificação mais elevada do ácido hialurónico, respetivamente. 
 De modo a obter uma expressão génica continuada os vectores foram 
combinados com a integrase do fago phiC31 para promover a integração do 
transgene no genoma da célula de forma segura e eficaz. A estratégia combinada 
de entrega baseada em vectores de quitosano e integrase demonstrou expressão 
génica prolongada tanto de genes de pequena dimensão, como o gene que codifica 
para a proteína verde fluorescente (com aproximadamente 1 kb) como de genes de 
maiores dimensões como o gene da proteína centrossomal CEP290 (com 
aproximadamente 8 kb) várias semanas após a transfeção.  
 A administração subretiniana in vivo dos nossos vetores revelou transfeção 
eficiente e expressão do transgene continuada em células epiteliais pigmentadas de 
retina pelo menos 6 meses após a transfeção. Os nossos resultados indicam que 
esta abordagem baseada em vetores de quitosano pode ultrapassar as limitações 
de empacotamento encontradas nas técnicas de transferência de genes mediadas 
por vírus adeno-associados, mantendo um elevado perfil de segurança e expressão 
génica continuada, constituindo assim uma alternativa para a terapia génica na 
retina.  
 
Palavras chave: Quitosano, Ácido hialurónico, Terapia génica, Retina, Vetores não-
virais.
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Abstract 
 
The success of gene therapy relies on efficient gene transfer and stable 
transgene expression. Our goal was to develop non-viral vectors optimized for retinal 
gene therapy with continued gene expression. Polymers, chitosan and hyaluronic 
acid or the modified polymers (thiolated chitosan and aminated hyaluronic acid) were 
chosen considering their biocompatibility and biodegradability to prepare several 
formulations. Vectors were formulated and characterized regarding their physical 
properties, biocompatibility and gene transfer efficiency in vitro on both retinal 
pigment epithelial and HEK293 cells and gene expression in the mouse retina.  
 Our results show that our vectors exhibit size and surface charge consistent 
with gene delivery. They also present long-term stability in both storage and 
physiological conditions, remain stable after several freeze-thaw cycles and are 
capable of efficiently protecting DNA from nuclease degradation.  
 Transfection studies show that transfection efficiency and transgene 
expression is affected by cell type, polymer molecular weight and mode of integrase 
delivery with the polyplexes. The incorporation of hyaluronic acid affected 
formulation stability, as expected, but it did not affect DNA loading and protection. 
The combination of chitosan and hyaluronic acid in polyplexes showed a significant 
improvement of transfection efficiency compared to chitosan-based vectors. In order 
to achieve sustained gene transfer vectors were combined with phiC31-integrase to 
promote transgene integration. The combined strategy of chitosan-based delivery 
and integrase demonstrate prolonged gene expression of both small (GFP, 1 Kb) 
and large genes (CEP290, 8Kb) several weeks post-transfection.  
In vivo sub-retinal administration of our vectors showed efficient transfection 
and sustained transgene expression in RPE cells at least 6 months post- injection. 
Our results indicate this chitosan-based approach may overcome size limitations 
found in commonly used adeno-associated viruses mediated gene transfer, while 
maintaining a high safety profile and prolonged, sustained gene expression, thus 
constituting an alternative for retinal gene delivery. 
 
KEYWORDS: Chitosan, Hyaluronic acid, Gene therapy, Retina, Non-viral vectors. !
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 Chapter I – General Introduction 
 
1. Gene therapy 
 
Gene therapy can be defined as a medical treatment by the transfer of 
therapeutic genetic material, DNA or RNA, into a group of cells (tissue or organ) in 
order to correct or modify expression of the gene influencing a disease process. [1] 
Gene therapy can be achieved in three ways:  
i) Substitution of altered genes, where genetic mutations causing loss of 
function can be corrected by replacement of the defective gene and repair of the 
mutated sequence; [2, 3]  
ii) Inhibition or counteraction of deleterious effects, which can be carried out 
by targeted inhibition of gene expression. This process occurs by blocking 
promoters, interfering with the mechanisms of gene expression using antisense 
RNAs, that are complementary to mRNA, bind and block them, or more recently, 
using siRNA (small interfering RNA), which block specific RNA sequences, 
neutralizing the mutated mRNA transcript and preventing it from being translated into 
a protein; [2, 3] and  
iii) Insertion of new genes. This can be achieved by targeted deletion of 
specific cells through the insertion of suicide genes that destroy their host cell or 
stimulators of the immune response genes. A copy of the normal gene can also be 
inserted to replace the function of the mutant gene that does not produce the correct 
protein. [2] 
Gene therapy can be used in the treatment of genetic or acquired diseases 
and is currently used to treat diseases such as cancer, peripheral vascular diseases, 
arthritis, neurodegenerative disorders and AIDS (Fig. 1.1). For example, gene 
therapy can be used to treat cancer by delivering to the tumor a gene encoding for 
an enzyme that will activate a pro-drug with no adverse effects for healthy cells. [4]  
An ideal targeted gene therapy should be i) a gene delivery technique that is 
efficient and non-toxic; ii) well characterized in terms of the genetic basis of the 
disease, or its biochemical basis, so that the appropriate therapeutic approach can 
be selected; iii) controlled in a way that cells and tissues can support levels of gene 
product expression; iv) able to demonstrate proof of principle in an experimental 
animal model of the disease for preclinical testing of the therapy. [5] 
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Figure 1.1 – Diversity in gene therapy clinical trials: A) focused diseases, B) strategies used 
and C) types of genes delivered. Adapted from Wiley clinical trial database 
(http://www.abedia.com/wiley/). 
 
The efficiency of in vivo gene therapy is determined by the choice of method 
or vector used to deliver the gene, the route of administration and the selected gene 
and target cells. [6, 7] While some requirements are common to several strategies, 
some depend on the targeted disease and transgene product. For example, 
characteristics of the target cells (location, life span, and blood flow rate) are 
A"
B"
C"
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determinant for the efficacy of gene therapy. Consequently, it is unlikely that a single 
system will be suitable for all applications. [7] 
Other factors governing the success of gene therapy are cell-specific gene 
transfer, levels and duration of transgene expression. Regarding cell specificity, 
besides the use of different delivery routes, the use of a tissue or cell specific 
promoter is one of the strategies for achieving targeted gene transfer. Since some 
promoters are only active in a specific type of cell, high specificity of transgene 
expression can be achieved. For example, the rhodopsin promoter drives expression 
in rod photoreceptors, and the human red opsin promoter drives expression in cone 
photoreceptors. [8] Still, cell specific promoters tend to have a weak transduction 
efficiency that limits their usefulness. [7]  
Considering levels of transgene expression in target cells, these can be 
directly correlated with the efficacy of the gene transfer approach, which in turn 
depends on the strength of the promoter and the amount of DNA that reaches the 
nucleus of target cells. The number of transformed cells and number of DNA copies 
taken up by each cell determine the levels of transgene expression. [7] Various ways 
to enhance the levels of expression have been examined to increase the amount of 
DNA in the cytoplasm, such as the use of fusogenic lipids or peptides to disrupt the 
endosomal membrane and the use of vectors with a high buffering capacity and the 
ability to swell when protonated. Other strategies aim at increasing the amount of 
DNA that reaches the nucleus using nuclear localization signals (NLS) that actively 
target DNA to the nucleus. [7]    
Since most gene delivery methods do not undergo chromosomal integration, 
the degradation of DNA and the transcriptional inactivation of the promoter are the 
major causes for the loss of transgene expression. Approaches to extend transgene 
expression involve the continuous supply of DNA to target cells by controlled release 
systems; improved DNA stability with the use of optimized promoters; and/or reduce 
the CpG content, known to have an immunostimulatory effect. [7] The obstacles to 
gene therapy will be discussed in more detail in section 3.  
 
2. Gene delivery systems  
 
A successful gene therapy strategy requires a safe and effective gene 
delivery system as well as the appropriate gene delivery method. Since naked DNA 
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molecules cannot effectively enter to the cell due to their hydrophilic nature, large 
size and negative charge derived from the phosphate groups in its backbone, 
several methods have been developed to ensure gene transfer to target cells. [4] 
Current delivery methods can be divided into two major classes: viral and 
non-viral. Non-viral delivery methods can further be classified as physical and 
chemical methods. 
 
 2. 1. Viral gene delivery 
 
Viral-mediated gene delivery systems use recombinant, replication-deficient 
viruses to deliver and express genes carried in their modified viral genome using the 
cell’s own machinery. [4, 9] Recombination is achieved by deleting all, or some, of 
the coding regions from the viral genome, but leaving intact sequences that are 
required for packaging the vector genome into the viral capsid or integration of vector 
DNA into the host chromatin. [10] Viral gene transfer is currently further advanced in 
terms of development due to its high efficiency, specificity in cell entry and gene 
expression. [9] 
Viral vectors are derived from five main classes of clinically applicable viruses: 
adenoviruses, retroviruses, lentiviruses, adeno-associated and herpes simplex-1 
viruses. These can be categorized into integrating and non-integrating vectors. 
Integrating vectors (e.g. adeno-associated viruses, retroviruses and lentiviruses) 
have the ability to integrate into the chromosomal DNA of the host cell, which will 
possibly allow lifelong gene expression. Non-integrating viruses (e.g. adenoviruses 
and herpes simplex-1 viruses) deliver their genomes into the nucleus of the target 
cell, where they remain episomal. [10, 11] 
However, these systems have some limitations, including the use of viruses 
during the production stage (helper viruses), immunogenicity, oncogenicity, toxicity 
and lack of optimization in large-scale production. [4] Some of the most important 
characteristics of viral vectors are summarized in Table 1.1. 
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Table 1.1 – Main properties of viral gene therapy systems. 
* AAV genome integration is rep protein dependant. dsDNA – double stranded DNA, ssDNA – single stranded DNA
Transfection 
vector 
Viral 
genome 
Packaging 
capacity Tropism Integration Advantages Limitations Refs 
Adenoviruses 
vectors dsDNA 8 – 36 kb 
Broad 
(dividing and 
non-dividing 
cells) 
No 
High efficacy 
transduction in most 
tissues 
Immune and 
inflammatory 
responses, short-term 
gene expression due to 
episome loss 
[4, 9-
11] 
Adeno-
associated 
vectors  
ssDNA <5 kb 
Broad 
(dividing and 
non-dividing 
cells) 
90% 
episome 
10% 
integrated* 
Site specific integration 
by non-homologous 
integration, non-
pathogenic 
Limited transgene 
capacity, pre-existing 
immunity due to natural 
infection 
[9-
11]!
Retroviral 
vectors RNA 8 kb 
Dividing cells 
only Yes 
Transgene persistence 
in dividing cells 
Low efficiency in vivo, 
risk of insertion 
mutagenesis 
[4, 9, 
11]!
Lentivirus 
vectors RNA 8 – 18 kb 
Broad 
(dividing and 
non-dividing 
cells) 
Yes 
Transgene persistence 
in dividing cells, low 
immunogenicity 
Difficult design and 
construction, risk of 
insertion mutagenesis 
[9, 
11, 
12]!
Herpes simplex 
virus vectors dsDNA 40 – 150 kb 
Broad 
(dividing and 
non-dividing 
cells) 
No 
Large transgene 
capacity, strong tropism 
for neurons 
Short-term gene 
expression due to 
episome loss 
[9-
11]!
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2. 2. Non-Viral gene delivery 
 
 Non-viral delivery systems can be classified according to preparation, as 
physical or chemical. In broad terms, physical delivery methods employ a physical 
force to increase permeability of the cell membrane and achieve gene delivery, while 
chemical methods utilize natural or synthetic carriers to perform a similar task. 
Compared to viral delivery systems, non-viral vectors are less toxic, less 
immunogenic, easily produced and have the potential for repeated administration. 
However, they are still less effective and can rarely accomplish transgene 
expression at therapeutic levels. [4, 13, 14]   
 
2. 2. 1. Physical methods 
 
Initially, gene therapy was done using the simplest gene transfer system that 
is the injection of naked plasmid DNA. However, naked DNA once inserted into the 
cell is rapidly degraded by nucleases in the serum and clearance by the 
mononuclear phagocyte system resulting in generally low transfection efficiency and 
transient expression. [6, 15] Gene transfer with naked DNA is highly ineffective 
unless the DNA is associated with other molecules and/or physical energy is applied 
to help cell entry. [16] 
Physical delivery methods may circumvent some of the limitations associated 
with other approaches, such as limited packaging of large genes. However, most 
require labor-intensive protocols and/or the use of costly instruments. [9] 
Several methodologies have been developed to enhance the transfection 
efficiency using physical methods that act by bringing DNA into the vicinity of the cell 
membrane and/or cause temporary disruption of the cell membrane, thus increasing 
DNA cell entry. [16] Among others, examples of such methods are electroporation, 
jet injection, gene gun, ultrasound, gene transfer by laser beam, which are described 
next. 
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Electroporation 
 
Electroporation, also known as electropermeabilization, is a delivery method 
that introduces foreign DNA into cells through an electric pulse that creates 
temporary pores in the cellular membrane. [6, 17] The pore formation is a very rapid 
event, occurring within 10 nanoseconds after electroporation and the size of the pore 
is estimated to be <10 nm in diameter. It is believed that small molecules, such as 
nucleic acids, can enter cells through these pores into the cytoplasm, by diffusion or 
a local electrophoretic effect. [6, 16]  
Electroporation can be done in vivo by local insertion of electrodes into the 
tissue or by holding the tissue with plate-type electrodes. It has been successfully 
applied to a range of tissues such as skin, kidney, lung, liver, muscle, joints, spinal 
cord, brain, retina, cornea, vasculature and solid tumors. [6, 16] In vivo 
electroporation has shown increases in transgene expression up to 1000-fold, 
compared with injection of naked pDNA without electroporation. [6, 7] However, 
electroporation has some limitations such as tissue damage associated with the 
procedure and limited transfection efficiency due to low tissue penetration. [6]  
 
Jet injection 
 
 Jet injection is a needle-free delivery method that uses high-speed pressure 
forcing DNA to penetrate the target tissue. Although jet injection is well tolerated by 
the target tissues its transfection efficiency is generally low. [17] 
  
Gene gun 
 
Gene gun delivery, also known as bioballistics or DNA-coated particle 
bombardment, uses a high-voltage electric discharge device that accelerates the 
DNA-coated particles to high velocity, enabling efficient penetration of target organs, 
tissues, or cells. DNA can be coated with microparticles of gold, tungsten or silver in 
order to increase density. [17] This technique can target the cell nucleus directly and 
has been used successfully in skin, liver, and muscle cells after surgical exposure of 
the tissue. [6] 
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The main advantages of this delivery system are the absence of toxic 
chemicals, no need for specific receptors, ability to transport DNA fragments of 
various sizes, high reproducibility and easy production of metal particles. 
Nevertheless, gene expression is generally low and short-termed. [4]   
 
Ultrasounds 
 
Ultrasounds can be used not only as a diagnostic tool but also as a 
therapeutic device. Gene transfer by ultrasounds, also known as sonoporation, uses 
acoustic cavitation that induces cell membrane permeabilization. [6, 17] In diagnostic 
applications low-intensity ultrasounds are used to prevent biological effects, whereas 
in therapeutic applications the intensity of the ultrasound energy is increased. [4]  
The major advantages of this technique are its safety and noninvasiveness. 
However, the success of sonoporation depends largely on the tissue type since 
ultrasounds suffer loss of intensity due to absorption, deflection and refraction 
phenomena within the tissue. [17] 
 
Gene transfer by laser beam 
 
 Laser beam gene transfer is similar to electroporation: naked DNA is injected 
into the target site followed by direct application of a laser beam instead of an 
electrical pulse. This method is considered safe, effective and reproducible for 
intradermal gene delivery. Compared with electroporation it causes substantially less 
damage. [17]     
 
Magnetofection 
 
 Gene transfer by magnetic force, also known as magnetofection, uses 
magnetic fields to achieve transfection of DNA bound to magnetic particles. The 
major advantages of this technique are rapid and efficient transfection at low vector 
doses. [17]   
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2. 2. 2. Chemical delivery methods 
 
In order to protect the therapeutic genetic material and enable a more efficient 
delivery, different chemical methods have been developed. Among these, cationic 
lipid- and polymer-based systems have been the most extensively studied. Lipids 
and polymers can interact with plasmid DNA and form nano-sized complexes, 
lipoplexes and polyplexes, respectively, that can pass through the cell membrane. 
Other chemical delivery methods include the use of inorganic compounds and 
synthetic peptides.   
 General mechanisms of transfection with lipidic and polymeric carriers involve 
particle cell surface bind by non-specific, electrostatic interactions between the 
positively charged carriers and the negatively charged cell surface, and cell entry by 
endocytosis or endocytosis-like mechanisms. Once inside the endosomes, the pH 
decreases from 7 to 5.5 and part of the bound nucleic acids escape into the 
cytoplasm, by mechanisms that differ for lipid- and polymer-based systems. Then, 
the carriers dissociate and the released nucleic acids can enter the nucleus by two 
hypothesized pathways, either passive DNA entry into the nucleus during mitosis or 
active import of the DNA through nuclear pores. [18] 
 
2. 2. 2. 1. Inorganic compounds 
 
Inorganic nanoparticles can be prepared from metals (iron, gold, silver), 
inorganic salts, or ceramics (phosphate or carbonate salts of calcium, magnesium, or 
silicon). [13] One of the first inorganic particles to be used for gene therapy was a 
calcium phosphate particle. Calcium phosphate gene transfer is mediated by DNA-
hydroxyapatite particles. DNA-calcium phosphate co-precipitates spontaneously in 
supersaturated solutions, however, to achieve high transfection, precipitates have to 
be generated under strict conditions, because the formation of DNA-hydroxyapatite 
particles is affected by calcium, phosphate and DNA concentrations, temperature 
and reaction time. This technique has been widely used and is considered easy-to-
use, cost-effective and highly safe. [9] 
 
 
  Chapter I !
! 11!
2. 2. 2. 2. Lipid-based systems 
 
Lipid-based systems are generally comprised of cationic lipids, amphiphilic 
molecules containing a positively charged hydrophilic head and hydrophobic tail. [18] 
Most common hydrophilic head groups are primary, secondary, or tertiary amines, or 
quaternary amine salts that are positively charged and can interact with negatively 
charged phosphate groups in nucleic acids. Structural properties of the lipid and 
charge ratio used are very important for the formation of lipid/DNA complexes and 
for the transfection effectiveness. [4] Depending on the ratio of positive charges on 
the lipids and negative charges in the DNA phosphodiester bonds, lipid complexes 
can be anionic, neutral or cationic. It is general belief that a slight excess of positive 
charges promotes higher transfection efficiencies due to electrostatic interactions 
between complexes and the cell membrane as well as negatively charged 
proteoglycans. [18]  
Cationic lipid/DNA complexes (lipoplexes) have been used in several clinical 
trials, which largely validate the concept of human gene therapy. Lipoplexes are 
formed in a self-assembly process triggered by DNA-mediated fusion of liposomes 
and involves a large-scale lipid rearrangement. [19] Plain lipoplexes can form two 
types of structures: a multilamellar structure with DNA monolayers sandwiched 
between cationic membranes or an inverted hexagonal structure with DNA 
molecules encapsulated within cationic lipid monolayer tubes. [18] Cationic lipids 
also have detergent and/or buffering properties that are thought to facilitate DNA 
release enhancing transfection efficiency. [19] One of the factors limiting the use of 
lipoplexes is its instability in biological fluids. In the presence of serum lipoplexes 
aggregate and their interaction causes its disintegration, which leads to DNA release 
and degradation. The rate of aggregation and disintegration is dependent on the 
structure of cationic and helper lipids. [19] Some examples are given in Table 1. 2.  
Liposomes, the most common lipid based gene delivery systems, are colloidal 
systems with membrane-like spherical structures composed by fatty acids or 
phospholipids with one or more lipid layers surrounding an aqueous core. [4, 9] 
Typically liposomes contain at least two components, a cationic lipid and a neutral 
lipid also referred to as helper lipid. [18] Liposome formation is influenced by several 
factors such as preparation procedure, mixing ratio, pDNA concentration, size of the 
cationic lipid and ionic strength of the buffer used in the preparation. [9] Parameters 
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like size, number of layers, and surface charge are determinant for the performance 
of liposomes in vitro and in vivo. [4] Several cationic lipids, such as quaternary 
ammonium detergents, cationic derivatives of cholesterol and diacylglycerol, and 
lipid derivatives of polyamines have been investigated for liposome-based gene 
delivery. [20] 
 
Table 1. 2 – List of commonly used lipids in gene therapy. Adapted from [13] 
Name 
Common 
abbreviation 
Feature 
1,2-Dioleoyl-sn-glycero-3-phosphatidylcholine   DOPC Helper lipid 
1,2-Dioleoyl-sn-glycero-3-
phosphatidylethanolamine 
DOPE Helper lipid 
Cholesterol Chol Helper lipid 
N-[1-(2,3-Dioleyloxy)propyl]N,N,N-
trimethylammonium chloride   
DOTMA  Cationic lipid 
1,2-Dioleoyloxy-3-trimethylammonium-propane DOTAP  Cationic lipid 
Dioctadecylamidoglycylspermine DOGS Cationic lipid 
1,2-Dioleyl-3-trimethylammonium-propane DOPA Cationic lipid 
6-Lauroxyhexyl ornithinate LHON Cationic lipid 
Ethyldimyristoylphosphatidylcholine EDMPC Cationic lipid 
N-Palmitoyl D-erythro-sphingosyl carbamoyl-
spermine 
CCS Cationic lipid 
N1-Cholesteryloxycarbonyl-3,7-diazanonane-
1,9-diamine 
CDAN Cationic lipid 
3β-[N-(N′,N′-Dimethylaminoethane)-
carbamoyl]cholesterol 
CD-Chol Cationic lipid 
1,2-Distearoyl-sn-glycero-3-
ethylphosphocholine 
DSEPC Cationic lipid 
  
In general, liposomes are considered non-toxic and biodegradable. However, 
their cationic nature may cause non-specific interactions with negatively charged 
cellular components resulting in reduction of cellular adhesion, hemolysis, and low 
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transfection efficiency compared to viral vectors. [9, 21] There is also the issue of 
potential cytotoxicity mainly caused by their cationic nature and the linker group. [9] 
Recent developments have focused on optimizations to improve transfection 
efficiency and reduce cytotoxicity by modifications of the positively charged 
headgroup or the linker functionalization group. Other strategies have conjugated 
cationic liposomes with polyethylene glycol (PEG) and/or other molecules such as 
ligands and peptides to improve stability. [9] 
 
2. 2. 2. 3. Polymer-based systems 
 
A successful gene delivery system should protect the negatively charged 
phosphate DNA backbone from anionic cell surface repulsion, should provide nano- 
or micro-sized structures in order to be compatible with endocytosis or phagocytosis 
and should protect DNA from extracellular and intracellular nuclease degradation. In 
order to achieve this, three strategies are currently used to produce polymer-based 
vectors: electrostatic interactions, encapsulation and adsorption, as shown in Fig. 
1.2. [4]  
Polymers are composed of small repeating molecules called monomers that 
form long-chained structures. Polymers can be homopolymers if they are composed 
of just one repeating monomer or copolymers if they are composed of two or more 
monomers. [4]  
Polymer DNA binding generally occurs by both hydrophobic and electrostatic 
interactions; the latter develop between DNA phosphate groups and polymer cationic 
groups, usually amine groups. Polymer DNA biding affinity is influenced by their 
intrinsic properties such as number of charged groups per polymer molecule, type of 
charged groups (primary, secondary, terciary amino groups, quaternary ammonium 
groups, amidine groups), spacing of charged groups within the polymer, degree of 
branching in the polymer backbone and hydrophobicity. [22] Interactions with DNA 
are pH-dependent in which higher charge-density polymers show stronger DNA 
binding. However, stronger biding can have an adverse effect on transfection 
efficiency since it can hamper DNA release to the cytoplasm. [23]  
Cationic polymers, unlike cationic lipids, do not contain a hydrophobic moiety 
and are water-soluble. Also, compared to cationic liposomes they form relatively 
smaller complexes with DNA, which can facilitate transfection. [18, 21] Polyplexes 
  Chapter I !
! 14!
can condensate into spherical, globular, rod-like or toroid structures. [18] Another 
approach to polymer-based delivery is the use of dendrimers. Dendrimers are 
repeating, branched, large spherical molecules, and have functional groups on their 
surface that can be used for modification and optimization. [4] The degree of 
polymerization of dendrimers is given by the number of generations of repeated 
branching cycles during its synthesis. [4] 
 
Figure 1.2 – DNA packaging strategies. Three strategies can be used to package DNA in 
polyplexes: electrostatic interactions, encapsulation within or adsorption onto biodegradable 
nano- or microspheres. Adapted from [24]. 
 
Cationic polymer/DNA complexes (polyplexes) have been actively studied as 
gene delivery systems and are a safe, biodegradable and non-toxic promising 
alternative to viral therapy. [9] Polyplex formation is influenced by several conditions, 
such as: ionic strength of the polyplex solution, concentration and positive/negative 
charge ratios of polymer and DNA and process of polyplex formation (kinetic vs. 
thermodynamic process). [13] These also affect the stability of the carrier and 
consequently its transfection efficiency. [18]  
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Polyplexes rely on endocytosis of polymer-based carriers for gene delivery 
and have showed triggered nucleic acid release, structural diversity and relatively 
higher transfection efficiency and stability than liposomes as well as more efficient 
DNA condensation. [9, 19, 21] A positive surface charge is required for efficient 
cellular uptake since the cell entry process encompasses interactions with cell-
surface proteoglycans.  [18] 
Selecting the most appropriate polymer for gene delivery is difficult due to 
structural differences and requires the characterization of chemical, mechanical, and 
biological features of the polymer. [4] Numerous kinds of polymers have been 
examined for gene delivery and the majority of these cationic polymers are derived 
from polyamines such as polylysine, polyarginine, chitosan, polyethylenimine and 
polyamidoamine dendrimers. [9] 
Several different types of polymers, both synthetic and natural have been 
evaluated as gene delivery vehicles. The most commonly used polymers are listed in 
Table 1.3. In many cases, polymers are chosen to address one of the particular 
barriers gene delivery faces, for example, DNA packaging and in vivo stability, 
biocompatibility or endosomal escape. [22]  
 
2. 2. 2. 3. 1. Synthetic polymers 
 
Among synthetic polymers, polyethylenimines (PEIs) are the most promising 
and the ones of most use in gene therapy. PEIs have strong DNA condensation 
capacity and intrinsic endosome-buffering properties that enable them to mediate 
efficient gene transfer. [9] They have been used with different molecular weights, 
branched or in a linear form resulting in variable levels of transfection efficiency and 
toxicity. [19]  
One of the factors influencing PEI-mediated transfection efficiency is PEI 
molecular weight (MW). High MW PEIs have been associated with higher 
transfection efficiencies along with acute cytotoxicity due to cell membrane 
disruption, followed by induction of apoptosis, while low MW PEI has been 
associated to low cytotoxicity and low transfection efficiencies. [9, 13] Besides 
toxicity, PEIs have other drawbacks like tendency to aggregate red blood cells, bind 
complement components and poor degradability. [9]  
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Table 1. 3 – List of polymers commonly used in gene therapy. Adapted from [13, 24] 
Name Common abbreviation Feature Structure 
Polyethylenimine PEI Cationic synthetic polymer  
 
Chitosan CS Natural polysaccharide  
 
Poly(ethylene)glycol PEG Inert synthetic polymer 
 
Poly(L-lysine) PLL Cationic synthetic polymer 
 
Poly(N-vinylpyrrolidone) PVP Neutral synthetic polymer 
 
Triethylenetetramine TETA Cationic synthetic  
 
Poly(D,L-lactic-co-glycolic acid) PLGA 
Biodegrabable synthetic 
polymer 
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